Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heparin-induced thrombocytopenia].

Massimo Franchini, Dino Veneri

    Recenti Progressi in Medicina
    |October 19, 2005
    PubMed
    Summary

    Heparin-induced thrombocytopenia is a severe adverse drug reaction. Recent advances improve understanding of its pathophysiology, diagnosis, and treatment.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    An unusual case of sodium citrate-dependent artifactual platelet count.

    Interventional medicine & applied science·2022
    Same author

    Pathogenesis of immune thrombocytopenia in common variable immunodeficiency.

    Autoimmunity reviews·2020
    Same author

    Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?

    Tumori·2019
    Same author

    Eltrombopag for the treatment of inherited thrombocytopenias: a phase II clinical trial.

    Haematologica·2019
    Same author

    Calcium-Dependent Src Phosphorylation and Reactive Oxygen Species Generation Are Implicated in the Activation of Human Platelet Induced by Thromboxane A2 Analogs.

    Frontiers in pharmacology·2018
    Same author

    Primary sphenoid lymphoma: Focus on imaging.

    Tumori·2018

    Area of Science:

    • Pharmacology
    • Hematology
    • Immunology

    Background:

    • Heparin-induced thrombocytopenia (HIT) is a life-threatening immune-mediated complication of heparin therapy.
    • It is characterized by a significant drop in platelet count and an increased risk of thrombosis.
    • HIT is often underestimated, leading to delayed diagnosis and management.

    Discussion:

    • Recent research has elucidated the complex immunological mechanisms underlying HIT, involving antibodies against platelet factor 4 (PF4).
    • Advances in diagnostic strategies, including functional assays and immunoassay techniques, enhance early and accurate detection.
    • Current treatment paradigms focus on immediate heparin cessation and initiation of alternative anticoagulants.

    Key Insights:

    • Understanding the pathophysiology of HIT is crucial for developing targeted therapies.
    • Accurate and timely diagnosis significantly improves patient outcomes and reduces thrombotic complications.
    • Effective management requires a multidisciplinary approach involving clinicians and laboratory specialists.

    Outlook:

    • Future research directions include the development of novel diagnostic tools and safer anticoagulant alternatives.
    • Continued investigation into the immunological basis of HIT may reveal new therapeutic targets.
    • Enhanced awareness and education are essential for mitigating the impact of this adverse drug effect.

    Related Experiment Videos